+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 180 Pages
  • December 2022
  • Region: Global
  • Grand View Research
  • ID: 4751806
The global liver cancer diagnostics market size is expected to reach USD 14.67 billion by 2030, advancing at a CAGR of 6.67% over the forecast period from 2023 to 2030. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic’s impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the ‘Breakthrough Device Designation’ from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

Liver Cancer Diagnostics Market Report Highlights

  • On basis of test type, laboratory tests held the largest share in 2022, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth
  • Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2022. The preference for these settings as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment’s growth
  • North America accounted for the highest share in 2022 due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth
  • Asia Pacific will exhibit the fastest growth during the forecast period of 2023-2030, owing to the prevalence of diseases and the presence of a large geriatric population in the region. In addition, the developing economies will boost the adoption of diagnostic tests in the region’s emerging countries

Table of Contents

Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Parent Market Analysis
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing Prevalence Of Liver Cancer
3.2.1.2 Rising Initiatives Undertaken By Public And Private Organizations
3.2.1.3 Increasing Prevalence Of Risk Factors For Liver Cancer
3.2.1.4 Technological Advancements
3.2.2 Market Restraint Analysis
3.2.2.1 High Cost Of Diagnostic Imaging
3.2.2.2 Radiation Exposure Likely To Limit Usage Of Ct
3.3 Penetration & Growth Prospect Mapping
3.4 Liver Cancer Diagonstics Market - Porter’s Analysis
3.5 Liver Cancer Diagonstics Market - Swot Analysis
3.6 Covid-19 Impact Analysis
Chapter 4 Test Type Business Analysis
4.1 Liver Cancer Diagonstics Market - Test Type Movement Analysis
4.2 Laboratory Tests
4.2.1 Global Laboratory Tests Market, 2018 - 2030 (USD Million)
4.2.2 Biomarkers
4.2.2.1 Global Biomarkers Market, 2018 - 2030 (USD Million)
4.2.2.2 Oncofetal And Glycoprotein Antigens
4.2.2.2.1 Global Oncofetal And Glycoprotein Antigens Market, 2018 - 2030 (USD Million)
4.2.2.3 Enzymes And Isoenzymes
4.2.2.3.1 Global Enzymes And Isoenzymes Market, 2018 - 2030 (USD Million)
4.2.2.4 Growth Factors And Receptors
4.2.2.4.1 Global Growth Factors And Receptors Market, 2018 - 2030 (USD Million)
4.2.2.5 Molecular Markers
4.2.2.5.1 Global Molecular Markers Market, 2018 - 2030 (USD Million)
4.2.2.6 Pathological Biomarkers
4.2.2.6.1 Global Pathological Biomarkers Market, 2018 - 2030 (USD Million)
4.2.3 Blood Tests
4.2.3.1 Global Bloos Tests Market, 2018 - 2030 (USD Million)
4.3 Imaging
4.3.1 Global Imaging Market, 2018 - 2030 (USD Million)
4.4 Endoscopy
4.4.1 Global Endoscopy Market, 2018 - 2030 (USD Million)
4.5 Biopsy
4.5.1 Global Biopsy Market, 2018 - 2030 (USD Million)
4.6 Others
4.6.1 Global Other Tests Type Market, 2018 - 2030 (USD Million)
Chapter 5 End-Use Business Analysis
5.1 Liver Cancer Diagonstics Market-End Use Movement Analysis
5.2 Hospitals & Diagnostic Laboratories
5.2.1 Global Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
5.3 Academic & Research Institutes
5.3.1 Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
5.4 Pharmaceutical & Cro Laboratories
5.4.1 Global Pharmaceutical & Cro Laboratories Market, 2018 - 2030 (USD Million)
Chaper 6 Regional Business Analysis
6.1 Liver Cancer Diagonstics Market: Regional Movement Analysis
6.2 North America
6.2.1 Swot Analysis
6.2.1.1 North America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 Competitive Scenario
6.2.2.3 U.S. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.2.3 Rest Of Europe
6.2.3.1 Key Country Dynamics
6.2.3.2 Competitive Scenario
6.2.3.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3 Europe
6.3.1 Swot Analysis
6.3.1.1 Europe Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.3.2 U.K.
6.3.2.1 Key Country Dynamics
6.3.2.2 Competitive Scenario
6.3.2.3 U.K. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Competitive Scenario
6.3.3.3 Germany Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 Competitive Scenario
6.3.4.3 France Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.5 Italy
6.3.5.1 Key Country Dynamics
6.3.5.2 Competitive Scenario
6.3.5.3 Italy Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.6 Spain
6.3.6.1 Key Country Dynamics
6.3.6.2 Competitive Scenario
6.3.6.3 Spain Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Competitive Scenario
6.3.7.3 Denmark Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Competitive Scenario
6.3.8.3 Sweden Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Competitive Scenario
6.3.9.3 Norway Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.10 Rest Of Europe
6.3.10.1 Key Country Dynamics
6.3.10.2 Competitive Scenario
6.3.10.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Swot Analysis
6.4.1.1 Asia Pacific Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Competitive Scenario
6.4.2.3 Japan Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 Competitive Scenario
6.4.3.3 China Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 Competitive Scenario
6.4.4.3 India Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.5 South Korea
6.4.5.1 Key Country Dynamics
6.4.5.2 Competitive Scenario
6.4.5.3 South Korea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.6 Australia
6.4.6.1 Key Country Dynamics
6.4.6.2 Competitive Scenario
6.4.6.3 Australia Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.7 Thailand
6.4.7.1 Key Country Dynamics
6.4.7.2 Competitive Scenario
6.4.7.3 Thailand Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.8 Rest Of Asia Pacific
6.4.8.1 Key Country Dynamics
6.4.8.2 Competitive Scenario
6.4.8.3 Rest Of Apac Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5 Latin America
6.5.1 Swot Analysis
6.5.1.1 Latin America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Competitive Scenario
6.5.2.3 Brazil Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Competitive Scenario
6.5.3.3 Mexico Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Competitive Scenario
6.5.4.3 Argentina Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5.5 Rest Of Latin America
6.5.5.1 Key Country Dynamics
6.5.5.2 Competitive Scenario
6.5.5.3 Rest Of Latam Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6 Middle East & Africa (Mea)
6.6.1 Swot Analysis
6.6.1.1 Mea Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 Competitive Scenario
6.6.2.3 South Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.3 Rest Of Middle East & Africa
6.6.3.1 Key Country Dynamics
6.6.3.2 Competitive Scenario
6.6.3.3 Rest Of Middle East & Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.4 Uae
6.6.4.1 Key Country Dynamics
6.6.4.2 Competitive Scenario
6.6.4.3 Uae Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Competitive Scenario
6.6.5.3 Kuwait Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.6 Rest Of Mea
6.6.6.1 Key Country Dynamics
6.6.6.2 Competitive Scenario
6.6.6.3 Rest Of Mea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Participant’s Overview
7.1.1 Abbott Laboratories
7.1.2 Thermo Fisher Scientific, Inc.
7.1.3 F. Hoffmann-La Roche Ltd.
7.1.4 Qiagen N.V.
7.1.5 Seimens Healthineers
7.1.6 Becton, Dickinson & Company
7.1.7 Fujifilm Medical Systems U.S.A., Inc.
7.1.8 Illumina, Inc.
7.1.9 Epigenomics Ag
7.1.10 Koninklijke Philips N.V.
7.2 Financial Performance
7.3 Participant Categorization
7.3.1 Market Leaders
7.3.1.1 Liver Cancer Diagnostics Market Share Analysis, 2022
7.3.2 Strategy Mapping
7.3.2.1 Expansion
7.3.2.2 Acquisition
7.3.2.3 Collaborations
7.3.2.4 Product/Service Launch
7.3.2.5 Partnerships
7.3.2.6 Others
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 4 Global liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 5 Global liver cancer diagnostics market, by region, 2018 - 2030 (USD Million)
Table 6 North America liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 7 North America liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 8 North America liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 9 U.S. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 10 U.S. liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 11 Rest of Europe liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 12 Rest of Europe liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 13 Europe liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 14 Europe liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 15 Europe liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 16 U.K. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 17 U.K. liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 18 Germany liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 19 Germany liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 20 France liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 21 France liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 22 Italy liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 23 Italy liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 24 Spain liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 25 Spain liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 26 Denmark liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 27 Denmark liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 28 Sweden liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 29 Sweden liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 30 Norway liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 31 Norway liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 32 Asia Pacific liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 33 Asia Pacific liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 34 Asia Pacific liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 35 Japan liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 36 Japan liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 37 China liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 38 China liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 39 India liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 40 India liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 41 South Korea liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 42 South Korea liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 43 Australia liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 44 Australia liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 45 Thailand liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 46 Thailand liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 47 Latin America liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 48 Latin America liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 49 Latin America liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 50 Brazil liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 51 Brazil liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 52 Mexico liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 53 Mexico liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 54 Argentina liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 55 Argentina liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 58 Middle East & Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 59 South Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 60 South Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 61 Rest of Middle East & Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 62 Rest of Middle East & Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 63 UAE liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 64 UAE liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 65 Kuwait liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 66 Kuwait liver cancer diagnostics, by end-use, 2018 - 2030 (USD Million)
Table 67 Participant’s overview
Table 68 Financial performance
Table 69 Key companies undergoing expansions
Table 70 Key companies undertaking acquisitions
Table 71 Key companies undergoing collaborations
Table 72 Key companies launching new products/services
Table 73 Key companies undergoing partnerships
Table 74 Key companies undertaking other strategies
List of Figures
FIG. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market summary, 2022 (USD Million)
Fig. 9 Market segmentation & scope
Fig. 10 Market driver impact
Fig. 11 Market restraint impact
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter’s analysis
Fig. 14 SWOT analysis
Fig. 15 Liver cancer diagnostics market: Test type outlook and key takeaways
Fig. 16 Liver cancer diagnostics market: Test type movement analysis
Fig. 17 Global oncofetal and glycoprotein antigens market, 2018 - 2030 (USD Million)
Fig. 18 Global enzymes and isoenzymes market, 2018 - 2030 (USD Million)
Fig. 19 Global growth factors and receptors market, 2018 - 2030 (USD Million)
Fig. 20 Global molecular markers readers market, 2018 - 2030 (USD Million)
Fig. 21 Global pathological biomarkers market, 2018 - 2030 (USD Million)
Fig. 22 Global blood tests market, 2018 - 2030 (USD Million)
Fig. 23 Global imaging market, 2018 - 2030 (USD Million)
Fig. 24 Global endoscopy market, 2018 - 2030 (USD Million)
Fig. 25 Global biopsy market, 2018 - 2030 (USD Million)
Fig. 26 Global other tests type market, 2018 - 2030 (USD Million)
Fig. 27 Liver cancer diagnostics market: End-use outlook and key takeaways
Fig. 28 Liver cancer diagnostics market: End-use movement analysis
Fig. 29 Global hospitals & diagnostic laboratories market, 2018 - 2030 (USD Million)
Fig. 30 Global academic & research institutes market, 2018 - 2030 (USD Million)
Fig. 31 Global pharmaceutical & CRO laboratories market, 2018 - 2030 (USD Million)
Fig. 32 Liver cancer diagnostics market: Regional outlook and key takeaways
Fig. 33 North America: SWOT Analysis
Fig. 34 North America liver cancer diagnostics market, 2018 - 2030 (USD Million)
Fig. 35 US key country dynamics
Fig. 36 US liver cancer diagnostics market, 2018 - 2030 (USD Million)
Fig. 37 Rest of Europe key country dynamics
Fig. 38 Rest of Europe liver cancer diagnostics market, 2018 - 2030 (USD Million)
Fig. 39 Europe: SWOT Analysis
Fig. 40 Europe liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 UK key country dynamics
Fig. 42 UK liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Germany key country dynamics
Fig. 44 Germany liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 France key country dynamics
Fig. 46 France liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Italy key country dynamics
Fig. 48 Italy liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Spain key country dynamics
Fig. 50 Spain liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Denmark key country dynamics
Fig. 52 Denmark liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Sweden key country dynamics
Fig. 54 Sweden liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Norway key country dynamics
Fig. 56 Norway liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Rest of Europe key country dynamics
Fig. 58 Rest of Europe liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Asia-Pacific: SWOT Analysis
Fig. 60 Asia-Pacific liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Japan key country dynamics
Fig. 62 Japan liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 China key country dynamics
Fig. 64 China liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 India key country dynamics
Fig. 66 India liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 South Korea key country dynamics
Fig. 68 South Korea liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Australia key country dynamics
Fig. 70 Australia liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Thailand key country dynamics
Fig. 72 Thailand liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Rest of Asia Pacific key country dynamics
Fig. 74 Rest of Asia Pacific liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Latin America: SWOT Analysis
Fig. 76 Latin America liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Brazil key country dynamics
Fig. 78 Brazil liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Mexico key country dynamics
Fig. 80 Mexico liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Argentina key country dynamics
Fig. 82 Argentina liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Rest of Latin America key country dynamics
Fig. 84 Rest of Latin America liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Middle East & Africa: SWOT Analysis
Fig. 86 Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 South Africa key country dynamics
Fig. 88 South Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Rest of Middle East & Africa key country dynamics
Fig. 90 Rest of Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 UAE key country dynamics
Fig. 92 UAE liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 Kuwait key country dynamics
Fig. 94 Kuwait liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Rest of Middle East & Africa key country dynamics
Fig. 96 Rest of Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Heat map analysis
Fig. 98 Market participant categorization
Fig. 99 Liver cancer diagnostics market share analysis, 2022
Fig. 100 Strategy framework

Companies Mentioned

  • Abbott Laboratories
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Qiagen N.V.
  • Seimens Healthineers
  • Becton, Dickinson & Company
  • Fujifilm Medical Systems U.S.A., Inc.
  • Illumina, Inc.
  • Epigenomics Ag
  • Koninklijke Philips N.V.

Methodology

Loading
LOADING...

Table Information